1-20 of 28
Prapti A. Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frontline Venetoclax (ven) Based Combination Therapy in Older Adults with Acute Myeloid Leukemia Treated in the Real-World Setting; A Multi-Institutional Retrospective Study

Prapti A. Patel, Yazan F. Madanat, Andrew J. Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4136.
DOI: https://doi.org/10.1182/blood-2021-153186
Published: 2021
Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis
Journal: Blood
Blood (2021) 138 (Supplement 1): 1279.
DOI: https://doi.org/10.1182/blood-2021-151234
Published: 2021
Journal Articles

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Uma Borate, Jennifer N. Saultz, Andy Kaempf, Jessica Minnier, Cristina E. Tognon, Stephen E. Kurtz, Christopher A. Eide, Prapti A. Patel, Yazan F. Madanat, Peter Clement, Sammantha Avaylon, Shikha Misra, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood
Blood (2021) 138 (Supplement 1): 2333.
DOI: https://doi.org/10.1182/blood-2021-152903
Published: 2021
Journal Articles

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

Jessica K. Altman, Bhavana Bhatnagar, Sameem Abedin, Amanda Przespolewski, Prapti A. Patel, Gary J. Schiller, Stanley Gill, Dhruva Patel, Linyi Fan, Ramon V. Tiu, Stephen A. Strickland
Journal: Blood
Blood (2021) 138 (Supplement 1): 2343.
DOI: https://doi.org/10.1182/blood-2021-150707
Published: 2021
Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Uma Borate, Prapti A. Patel, Chetasi Talati, Jessica Kohlschmidt, Michael P. Ozga, Yazan F. Madanat, Luke Fletcher, Ravi Patel, Krzysztof Mrózek, Deedra Nicolet, Akriti G Jain, Virginia Olivia Volpe, Fei Yang, Richard D. Press, Daniel Jones, James S. Blachly, Christopher J. Walker, Andrew J Carroll, Guido Marcucci, Maria R. Baer, William Blum, Bayard L. Powell, Jonathan E Kolitz, Richard A. Larson, Richard M. Stone, John C. Byrd, Alice S. Mims, Kendra Sweet, Ann-Kathrin Eisfeld
Journal: Blood
Blood (2021) 138 (Supplement 1): 226.
DOI: https://doi.org/10.1182/blood-2021-152838
Published: 2021
Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Clinical Trials & Observations
Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A. Pollyea, James K. McCloskey, Olatoyosi Odenike, Bob Löwenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Mark G. Frattini, Frederik Lersch, Aleksandra Franovic, Salah Nabhan, Bin Fan, Sung Choe, Hongfang Wang, Bin Wu, Lei Hua, Caroline Almon, Michael Cooper, Hagop M. Kantarjian, Martin S. Tallman
Journal: Blood
Blood (2021) 137 (13): 1792–1803.
DOI: https://doi.org/10.1182/blood.2020007233
Published: 2021
Includes: Supplemental data
Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Eytan M. Stein, MD, Ying Huang, MS, MA, Uma Borate, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark Litzow, MD, Tara Lin, MD, Prapti A. Patel, MD, Matthew C Foster, MD, Michael Boyiadzis, MD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A Heerema, PhD, Leonard Rosenberg, Ashley Owen Yocum, PhD, Timothy Chen, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Abigail Shoben, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
DOI: https://doi.org/10.1182/blood-2020-143265
Published: 2020
Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Michael R. Savona, MD, James K. McCloskey, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Aref Al-Kali, MD, Amer M. Zeidan, MBBS, MHS, H. Joachim Deeg, MD, Prapti A. Patel, MD, Mitchell Sabloff, MSc,MDFRCPC, Mary-Margaret Keating, MD FRCPC, Kim-Hien Dao, DO, PhD, Nancy Zhu, MD, Nashat Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Hagop M. Kantarjian, MD, Amy E. DeZern, MD, Casey L. O'Connell, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD DPhil, Harshad Amin, MD, Jasleen K. Randhawa, MD, Brian Leber, MD, Yong Hao, MD PhD, Harold N. Keer, MDPhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
DOI: https://doi.org/10.1182/blood-2020-133855
Published: 2020
Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
DOI: https://doi.org/10.1182/blood-2020-141619
Published: 2020
Journal Articles

A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML)

Courtney D. DiNardo, MD MSCE, Daniel A. Pollyea, Marina Konopleva, MD PhD, Kyu Hong, MS, Tao Huang, PhD, An Song, PhD, Elizabeth Wieland, MS, Paul Woodard, MD, Charlene Liao, PhD, Chengcheng Zhang, PhD, Prapti A. Patel, MD, Ahmed Aribi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
DOI: https://doi.org/10.1182/blood-2020-137665
Published: 2020
Journal Articles

Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study

Suleyman Y Goksu, MD, Jude Khatib, MD, Busra N Bacik Goksu, Rong Wang, PhD, Prapti A. Patel, MD, Madhuri Vusirkala, MD, Suzanne Cole, MD, Ahmet Seyhanli, MD, Muhammet Ozer, MD, Robert H. Collins, MD, Stephen Chung, MD, Amer M. Zeidan, MBBS, MHS, Yazan F. Madanat, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
DOI: https://doi.org/10.1182/blood-2020-140564
Published: 2020
Journal Articles

Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Yazan F. Madanat, MD, Hetalkumari Patel, PharmD, BCOP, Omik Patel, PharmD, BCOP, Jingsheng Yan, PhD, Jude Khatib, MD, Madhuri Vusirkala, MD, Suleyman Y Goksu, MD, Chul Ahn, PhD, Prapti A. Patel, MD, Robert H. Collins, MD, Stephen Chung, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43.
DOI: https://doi.org/10.1182/blood-2020-139794
Published: 2020
Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Courtney D. DiNardo, MD MSCE, Anthony S. Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, Hartmut Döhner, MD, Giovanni Martinelli, MD, Prapti A. Patel, MD, Emmanuel Raffoux, MD, Peter Tan, MBBS, Amer M. Zeidan, MBBS, MHS, Stephane De Botton, Richard M. Stone, MD, Mark Frattini, MD, Aleksandra Franovic, PhD, Emily Xu, PhD, Thomas Winkler, MD, Bin Wu, PhD, Paresh Vyas, MRCP, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–51.
DOI: https://doi.org/10.1182/blood-2020-136922
Published: 2020
Journal Articles

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Uma Borate, MD, Fei Yang, MD, Richard D. Press, MD PhD, Dean Pavlick, Luke Juckett, BSc, BA, MSc, Anupriya Agarwal, PhD, Amy Burd, PhD, Alice S. Mims, MD, Eytan M. Stein, MD, Prapti A. Patel, MD, Maria R. Baer, MD, Wendy Stock, MD, Gary J. Schiller, MD, William Blum, MD, Paul J Shami, MD, Mark Litzow, MD, James M. Foran, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, Sonja Marcus, MPH, Ashley Owen Yocum, PhD, Mona Stefanos, MBChB, John C. Byrd, MD, Brian J. Druker, Jo-Anne Vergilio, MD, Ross L. Levine, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 373.
DOI: https://doi.org/10.1182/blood-2019-131925
Published: 2019
Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

James M. Foran, MD, Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony Stein, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Abdulafeez Oluyadi, PharmD, Thomas Winkler, MD, Denice Hickman, BSN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4254.
DOI: https://doi.org/10.1182/blood-2019-123946
Published: 2019
Journal Articles

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Tara L. Lin, MD, Pamela S. Becker, MD PhD, Prapti A. Patel, MD, Eunice S. Wang, MD, Alexander I. Spira, PhD MD FACP, Michaela L. Tsai, MD, Maya Ridinger, Peter J Croucher, PhD, Mark Erlander, PhD, Sandra L Silberman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 230.
DOI: https://doi.org/10.1182/blood-2019-126262
Published: 2019
Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Guillermo Garcia-Manero, MD, James McCloskey, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Amer M. Zeidan, MBBS, MHS, Aref Al-Kali, MD, Kim-Hien Dao, DO, PhD, H. Joachim Deeg, MD, Prapti A. Patel, MD, Mitchell Sabloff, MSc,MDFRCPC, Mary-Margaret Keating, MD, Nancy Zhu, MD, Nashat Y. Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Aditi Shastri, MD, Amy E. DeZern, MD, Casey L. O'Connell, MD, Gail J. Roboz, MD, Aram Oganesian, PhD, Yong Hao, MD PhD, Harold N. Keer, MD PhD, Mohammad Azab, MD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 846.
DOI: https://doi.org/10.1182/blood-2019-122980
Published: 2019
Journal Articles

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Amy Burd, PhD, Ross L. Levine, MD, Amy S. Ruppert, MAS, PhD, Alice S. Mims, MD, Uma Borate, MD, Eytan M. Stein, MD, Prapti A. Patel, MD, Maria R. Baer, MD, Wendy Stock, MD, Michael W. Deininger, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, Mark Litzow, MD, James M. Foran, MD, Tara L. Lin, MD, Brian J Ball, Michael Boyiadzis, MD, Elie Traer, Olatoyosi Odenike, MD, Martha L. Arellano, MD, Alison R. Walker, MD, Vu H. Duong, MD, Robert H. Collins, MD, Nyla A. Heerema, PhD, Jo-Anne Vergilio, MD, TIm Brennan, PhD, Christine Vietz, Molly Vittorio, Leonard Rosenberg, Sonja Marcus, MPH, Ashley Owen Yocum, PhD, Mona Stefanos, MBChB, Brian J. Druker, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 175.
DOI: https://doi.org/10.1182/blood-2019-130201
Published: 2019
Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Uma Borate, MD, Amy S. Ruppert, MAS, PhD, Fei Yang, MD, Dan Jones, MD PhD, Sean Caruthers, Weiqiang Zhao, MD PhD, Jo-Anne Vergilio, MD, Amy Burd, PhD, Dean Pavlick, Luke Juckett, BSc, BA, MSc, Eytan M. Stein, MD, Prapti A. Patel, MD, Maria R. Baer, MD, Wendy Stock, MD, Gary J. Schiller, MD, William Blum, MD, Tibor Kovacsovics, MD, Mark Litzow, MD, James M. Foran, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, Sonja Marcus, MPH, Ashley Owen Yocum, PhD, Mona Stefanos, MBChB, Brian J. Druker, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2145.
DOI: https://doi.org/10.1182/blood-2019-131253
Published: 2019
Journal Articles

Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Alexander I Spira, MD, Prapti A. Patel, MD, Michaela L. Tsai, MD, Maya Ridinger, PhD, Sandra L Silberman, MD PhD, Mark Erlander, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4043.
DOI: https://doi.org/10.1182/blood-2018-99-112590
Published: 2018